BKBusra Kantarci-Demirkiran

Busra Kantarci-Demirkiran

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Busra Kantarci-Demirkiran has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Detection and Classification of Diabetic Macular Edema with a Desktop-Based Code-Free Machine Learning Tool

    by Furkan Kırık, Büşra Demirkıran, Cansu Ekinci Aslanoğlu, Arif Koytak, Hakan Özdemir

    To evaluate the effectiveness of the Lobe application, a machine learning (ML) tool that can be used on a personal computer without requiring coding expertise, in the recognition and classification of diabetic macular edema (DME) in spectral-domain optical coherence tomography (SD-OCT) scans. A total of 695 cross-sectional SD-OCT images from 336 patients with DME and 200 OCT images of 200 healthy controls were included. Images with DME were classified into three main types: diffuse retinal edema (DRE), cystoid macular edema (CME), and cystoid macular degeneration (CMD). To develop the ML model, we used the desktop-based code-free Lobe application, which includes a pre-trained ResNet-50 V2 convolutional neural network and is available free of charge. The performance of the trained model in recognizing and classifying DME was evaluated with 41 DRE, 28 CMD, 70 CME, and 40 normal SD-OCT images that were not used in the training. The developed model showed 99.28% sensitivity and 100% specificity for class-independent detection of DME. Sensitivity and specificity by labels were 87.80% and 98.57% for DRE, 96.43% and 99.29% for CME, and 95.71% and 95.41% for CMD, respectively. To our knowledge, this is the first evaluation of the effectiveness of Lobe with ophthalmological images, and the results indicate that it can be used with high efficiency in the recognition and classification of DME from SD-OCT images by ophthalmologists without coding expertise.


  • Open Access

    The Comparison of Platelet‐Rich Plasma Versus Injectable Platelet Rich Fibrin in Facial Skin Rejuvenation

    by Nilhan Atsu, Cansu Ekinci-Aslanoglu, Busra Kantarci-Demirkiran, Nazli Caf, Fadime Nuhoglu

    Background/Objective. Platelet‐rich plasma (PRP) has a widespread use in various indications including dermatological conditions. Injectable platelet‐rich fibrin on the other hand is prepared without anticoagulants and seems to have a sustained action. This study aimed to compare PRP and PRF injection treatments for facial skin rejuvenation in terms of efficacy, patient satisfaction, and side effects. Patients and Methods. Patients who received facial intradermal injections of PRP or PRF for skin rejuvenation were included in this study. Patients received three injections one month apart and evaluated at follow‐up visits for cosmetic results using a high‐resolution UVA‐light video camera and a surface evaluation software at three regions (frontal, nasolabial, and canthal) as well as for patient satisfaction and side effects. Results. A significant marginal superiority of PRF over PRP was only evident for some canthal cosmetic parameters (canthal smoothness and wrinkles); however, the two groups did not differ in terms of other cosmetic regional parameters. For canthal smoothness, the difference was significant at three months. The two groups did not differ in terms of side effects, pain, and patient satisfaction. Conclusion. This study obtained slightly better outcomes with PRF injections when compared to PRP for facial rejuvenation only at canthal region and only at three months, which disappeared later during the treatment. PRF may represent a viable alternative to PRP for that indication owing to its easier preparation, absence of anticoagulants, and possibly its sustained effect. Further large studies are warranted.